In 2025, more than 316,000 women in the United States were expected to receive a breast cancer diagnosis, underscoring the significant health and economic challenges posed by the disease. Breast cancer carries the highest economic burden among major cancers, as detailed in a recent report examining the financing of cancer care with a focus on prevention, detection, and early diagnosis.

Early detection remains critical to improving survival outcomes. Approximately 92% of women diagnosed with breast cancer survive at least five years, though this rate declines sharply with the advancement of the disease stage at diagnosis. Survival approaches nearly 100% for cases where cancer is identified at a localized stage. In contrast, cervical cancer, which is highly preventable and detectable, still results in over 4,000 deaths annually, disproportionately affecting women with limited access to screening services.

Despite programs like the Centers for Disease Control and Prevention’s national breast and cervical cancer screening initiative—which has served more than 6.5 million low-income and underinsured women—the available funding remains inadequate. Operating on an annual budget of approximately $200 million, the program falls short of meeting the widespread need for affordable and accessible screening.

The report highlights a systemic market failure in the funding of cancer care. Although treating early-stage cancer can be substantially less costly than managing late-stage disease, financing models tend to prioritize treatment over prevention and early diagnosis. For breast cancer, treatment expenses escalate from tens of thousands of dollars at Stage 1 to nearly ten times higher by Stage 4, due to the complexity of therapies and extended care required for advanced disease. However, the financial benefits of early detection accrue across multiple stakeholders—including patients, insurers, employers, health systems, and government agencies—often over many years, complicating incentives for upfront investment in preventive measures.

To address this challenge, the report proposes several innovative financing solutions aimed at aligning financial incentives with long-term health outcomes. These solutions include syndicated investment funds that engage insurers and employers as co-investors in diagnostic technologies, thereby creating a shared interest in reducing future treatment costs. Additionally, revolving loan funds could enhance access to mammography equipment and screening services in underserved rural communities. The authors also suggest the issuance of cancer bonds, which would monetize anticipated future savings, providing immediate capital for prevention efforts. Furthermore, blended finance vehicles could deploy catalytic capital to de-risk investments in companies developing next-generation diagnostics such as liquid biopsies and multicancer early detection tests, bridging the gap between innovation and patient access.

These strategies seek to reform how cancer prevention and early detection are financed, aiming to extend the benefits of timely diagnosis to more women nationwide. The authors emphasize that investment in these areas is not merely an ancillary policy concern but a pivotal factor in reducing mortality and financial burden associated with cancer. Early detection offers not only improved survival but also the possibility of a life unshadowed by advanced disease, underscoring the urgency of redesigning funding mechanisms to support prevention-focused care.